Acquisitive Ireland-headquartered Shire (LSE: SHP) revealed this morning that it will acquire USA-based Dyax Corp (Nasdaq: DYAX) for $37.30 in cash per Dyax share, for aggregate upfront consideration of approximately $5.9 billion. This represents a 35.5% premium to Dyax' closing stock price on Friday.
Dyax shareholders may receive additional value through a non-tradable contingent value right (CVR) that will pay $4.00 in cash per Dyax share upon approval of DX-2930 in hereditary angioedema (HAE), representing a potential additional $646 million in aggregate contingent consideration. The transaction has been unanimously approved by the boards of directors of both Shire and Dyax and is expected to close in the first half of 2016.
Fifth M&A deal for Shire this year
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze